IMTX https://immatics.com/
Price Chart
Executive Summary
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, showing 56% confirmed ORR, 14.6-month median DOR, 6.1-month median PFS, and 16.2-month median OS with manageable safety. The Phase 3 SUPRAME trial remains on track with BLA submission expected in 1H 2027.
Actionable Insight
Positive efficacy and durability data reinforce anzu-cel's potential in melanoma; investors should watch for SUPRAME Phase 3 enrollment progress and any competitive developments. The 1H 2027 BLA submission timeline provides a medium-term catalyst.
Key Facts
- 56% confirmed objective response rate (cORR) in heavily pretreated metastatic melanoma (N=33)
- Median duration of response (mDOR) of 14.6 months; median PFS 6.1 months; median OS 16.2 months
- Phase 3 SUPRAME trial advancing; BLA submission targeted for 1H 2027
- Predictable and manageable safety profile with mostly Grade 1-2 CRS and infrequent ICANS
- Anzu-cel demonstrated systemic anti-tumor activity across multiple metastatic sites including liver, lung, and brain
Financial Impact
Positive clinical data supports the potential of anzu-cel as a first-in-class PRAME-directed cell therapy, though no financial figures provided.
Risk Factors
- Data is from Phase 1b; Phase 3 may not replicate results
- Competitive landscape includes approved checkpoint inhibitors and other cell therapies
- Regulatory approval and commercial launch are uncertain and costly
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
6-K
| $10.04 $10.21 | ▲ +1.64% | ▲ +2.34% | $9.79 (−2.49%) |
|
Jun 1, 2026
4d ago
|
6-K
| $11.14 $10.04 | ▼ −9.87% | ▼ −10.02% | $9.79 (−12.12%) |
|
Jun 1, 2026
4d ago
|
Press Release
| $11.14 $10.04 | ▼ −9.87% | ▼ −10.02% | $9.79 (−12.12%) |
|
May 31, 2026
5d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 30, 2026
6d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 12, 2026
24d ago
|
6-K
| $11.39 $10.79 | ▲ +5.27% | ▲ +5.84% | $9.79 (+14.05%) |
|
May 12, 2026
24d ago
|
Press Release
| $11.39 $10.79 | ▼ −5.27% | ▼ −5.84% | $9.79 (−14.05%) |
|
Apr 21, 2026
6w ago
|
6-K
| $11.18 $11.26 | ▲ +0.72% | ▼ −0.30% | $9.79 (−12.43%) |
|
Apr 21, 2026
6w ago
|
Press Release
| $11.18 $11.26 | ▲ +0.72% | ▼ −0.30% | $9.79 (−12.43%) |
|
Apr 17, 2026
7w ago
|
6-K
| $11.17 $11.25 | ▲ +0.72% | ▲ +0.91% | $9.79 (−12.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access